Amgen CEO Robert Bradway said the company's obesity drug could find its space in the market due to once-monthly dosing and expansion of manufacturing capabilities.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,